debiopharm - Robuta Search

https://apply.workable.com/debiopharm/j/7151CCF994/ P2607 - Medical Director, Oncology - Debiopharm At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned... medical director oncology debiopharm https://www.debiopharm.com/ Debiopharm - We develop for patients and their quality of life Jan 29, 2026 - Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in... we develop for patients debiopharm quality life https://www.biospace.com/debiopharm-announces-marketing-and-supply-agreement-for-trelstar-r-in-canada Debiopharm Announces Marketing And Supply Agreement For Trelstar(R) In Canada - BioSpace supply agreement https://apply.workable.com/debiopharm/j/6D1731B97E/ T2601 - Talent Acquisition & L&D Intern - Debiopharm Debiopharm is privately-owned Swiss biopharmaceutical company committed to research in oncology and infectious diseases in order to improve patient outcomes... talent acquisition intern debiopharm https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech May 24, 2017 - Debiopharm has bought a phase 2 a debiopharm buys immunogen adc grow https://www.prnewswire.com/news-releases/acquisition-of-debiopharms-investment-portfolio-company-kaiku-health-broadens-patient-access-to-digital-oncology-intervention-301064768.html Acquisition of Debiopharm's Investment Portfolio Company Kaiku Health Broadens Patient Access to... /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the successful exit and acquisition of their investment... https://apply.workable.com/debiopharm/j/F5778E08C8/ P2606 - Global Early Commercial Manager, Oncology - Debiopharm At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned... commercial manager global early oncology debiopharm https://www.biospace.com/debiopharm-s-a-and-dyax-corp-restructure-development-agreement-for-depelestat-in-pulmonary-disorders Debiopharm S.A. And Dyax Corp. Restructure Development Agreement For DEPELESTAT In Pulmonary... https://www.imd.org/news/strategy/updates-two-imd-mba-teams-rewarded-for-innovation-in-the-debiopharm-inartis-challenge/ Two IMD MBA teams rewarded for innovation in the Debiopharm Inartis Challenge - IMD business school... Apr 14, 2023 - Two IMD teams of IMD MBAs have been named among the winners of the Debiopharm Inartis Challenge, a competition organized to harness innovation to improve the... https://www.businesswire.com/news/home/20240326540510/en/Ubiquigent-and-Debiopharm-Enter-Agreement-to-Support-USP1-Inhibitor-Programme-for-Debio-0432 Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432 Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of h... https://www.businesswire.com/news/home/20251106401539/en/Debiopharm-Takes-a-Step-Forward-for-Children-With-CPP-Enrollment-Completion-for-the-Phase-III-Trial-Evaluating-the-First-Ever-Yearly-Injectable-Triptorelin-Formulation Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III... Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quali... https://www.imd.org/news/strategy/updates-imd-mba-team-wins-debiopharm-inartis-innovation-challenge-to-improve-lives-of-healthcare-patients/ IMD MBA team wins Debiopharm-Inartis innovation challenge to improve lives of healthcare patients -... Feb 24, 2023 - A team of IMD MBA students was recently officially recognized as winners in the prestigious Debiopharm-Inartis innovation challenge. Kicked off in December... https://www.biospace.com/salix-pharmaceuticals-ltd-and-debiopharm-s-a-sign-sanvar-r-license-agreement-worth-up-to-14-million Salix Pharmaceuticals, Ltd. And Debiopharm S.A. Sign SANVAR(R) License Agreement Worth Up To $14... https://www.fiercebiotech.com/biotech/repare-finds-suitor-paused-pkmyt1-inhibitor-current-partner-debiopharm Repare finds suitor for PKMYT1 inhibitor in partner Debiopharm Jul 16, 2025 - Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward. repare finds suitor pkmyt1 inhibitor